Literature DB >> 16870220

Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6.

Tomás Herraiz1, Hugo Guillén, Vicente J Arán, Jeffrey R Idle, Frank J Gonzalez.   

Abstract

1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin is a chemical inducer of Parkinson's disease (PD) whereas N-methylated beta-carbolines and isoquinolines are naturally occurring analogues of MPTP involved in PD. This research has studied the oxidation of MPTP by human CYP2D6 (CYP2D6*1 and CYP2D6*10 allelic variants) as well as by a mixture of cytochrome P450s-resembling HLM, and the products generated compared with those afforded by human monoamine oxidase (MAO-B). MPTP was efficiently oxidized by CYP2D6 to two main products: MPTP-OH (p-hydroxylation) and PTP (N-demethylation), with turnover numbers of 10.09 min-1 and Km of 79.36+/-3 microM (formation of MPTP-OH) and 18.95 min-1 and Km 69.6+/-2.2 microM (PTP). Small amounts of dehydrogenated toxins MPDP+ and MPP+ were also detected. CYP2D6 competed with MAO-B for the oxidation of MPTP. MPTP oxidation by MAO-B to MPDP+ and MPP+ toxins (bioactivation) was up to 3-fold higher than CYP2D6 detoxification to PTP and MPTP-OH. Several N-methylated beta-carbolines and isoquinolines were screened for N-demethylation (detoxification) that was not significantly catalyzed by CYP2D6 or the P450s mixture. In contrast, various beta-carbolines were efficiently hydroxylated to hydroxy-beta-carbolines by CYP2D6. Thus, N(2)-methyl-1,2,3,4-tetrahydro-beta-carboline (a close MPTP analog) was highly hydroxylated to 6-hydroxy-N(2)-methyl-1,2,3,4-tetrahydro-beta-carboline and a corresponding 7-hydroxy-derivative. Thus, CYP2D6 could participate in the bioactivation and/or detoxification of these neuroactive compounds by an active hydroxylation pathway. The CYP2D6*1 enzymatic variant exhibited much higher metabolism of both MPTP and N(2)-methyl-1,2,3,4-tetrahydro-beta-carboline than the CYP2D6*10 variant, highlighting the importance of CYP2D6 polymorphism in the oxidation of these toxins. Altogether, these results suggest that CYP2D6 can play an important role in the metabolic outcome of both MPTP and beta-carbolines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16870220     DOI: 10.1016/j.taap.2006.06.003

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  11 in total

1.  Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells.

Authors:  Amandeep Mann; Rachel F Tyndale
Journal:  Eur J Neurosci       Date:  2010-03-22       Impact factor: 3.386

2.  MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex.

Authors:  Giulia Costa; Nicola Simola; Micaela Morelli
Journal:  Psychopharmacology (Berl)       Date:  2014-04-01       Impact factor: 4.530

3.  Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models.

Authors:  Mrittika Chattopadhyay; Anindya Roy Chowdhury; Ting Feng; Charles-Antoine Assenmacher; Enrico Radaelli; F Peter Guengerich; Narayan G Avadhani
Journal:  J Biol Chem       Date:  2019-05-20       Impact factor: 5.157

4.  Assay of MAO Inhibition by Chromatographic Techniques (HPLC/HPLC-MS).

Authors:  Tomás Herraiz
Journal:  Methods Mol Biol       Date:  2023

Review 5.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

6.  Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease.

Authors:  Prachi Bajpai; Michelle C Sangar; Shilpee Singh; Weigang Tang; Seema Bansal; Goutam Chowdhury; Qian Cheng; Ji-Kang Fang; Martha V Martin; F Peter Guengerich; Narayan G Avadhani
Journal:  J Biol Chem       Date:  2012-12-20       Impact factor: 5.157

Review 7.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

8.  Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment.

Authors:  Amandeep Mann; Sharon Miksys; Anna Lee; Deborah C Mash; Rachel F Tyndale
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

9.  Metabolite profile resulting from the activation/inactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 2-methyltetrahydro-β-carboline by oxidative enzymes.

Authors:  Tomás Herraiz; Hugo Guillén; Juan Galisteo
Journal:  Biomed Res Int       Date:  2013-07-28       Impact factor: 3.411

10.  Harmaline tremor: underlying mechanisms in a potential animal model of essential tremor.

Authors:  Adrian Handforth
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.